BioCryst Pharmaceuticals, Inc. (BCRX)
7.65
-0.13
(-1.67%)
USD |
NASDAQ |
Oct 23, 16:00
7.64
-0.01
(-0.13%)
After-Hours: 20:00
BioCryst Pharmaceuticals Enterprise Value : 2.436B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.436B |
| October 22, 2026 | 2.470B |
| October 21, 2026 | 2.462B |
| October 20, 2026 | 2.510B |
| October 19, 2026 | 2.544B |
| October 16, 2026 | 2.472B |
| October 15, 2026 | 2.531B |
| October 14, 2026 | 2.538B |
| October 13, 2026 | 2.544B |
| October 12, 2026 | 2.618B |
| October 09, 2026 | 2.666B |
| October 08, 2026 | 2.600B |
| October 07, 2026 | 2.628B |
| October 06, 2026 | 2.513B |
| October 05, 2026 | 2.551B |
| October 02, 2026 | 2.569B |
| October 01, 2026 | 2.556B |
| September 30, 2026 | 2.610B |
| September 29, 2026 | 2.595B |
| September 28, 2026 | 2.646B |
| September 25, 2026 | 2.676B |
| September 24, 2026 | 2.658B |
| September 23, 2026 | 2.671B |
| September 22, 2026 | 2.725B |
| September 21, 2026 | 2.720B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.699B |
| September 17, 2026 | 2.704B |
| September 16, 2026 | 2.635B |
| September 15, 2026 | 2.567B |
| September 14, 2026 | 2.584B |
| September 11, 2026 | 2.556B |
| September 10, 2026 | 2.600B |
| September 09, 2026 | 2.731B |
| September 08, 2026 | 2.798B |
| September 04, 2026 | 3.026B |
| September 03, 2026 | 3.059B |
| September 02, 2026 | 3.080B |
| September 01, 2026 | 3.016B |
| August 31, 2026 | 2.960B |
| August 28, 2026 | 2.990B |
| August 27, 2026 | 3.003B |
| August 26, 2026 | 2.993B |
| August 25, 2026 | 2.993B |
| August 24, 2026 | 2.955B |
| August 21, 2026 | 2.921B |
| August 20, 2026 | 2.949B |
| August 19, 2026 | 3.054B |
| August 18, 2026 | 2.960B |
| August 17, 2026 | 3.021B |
| August 14, 2026 | 2.970B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 280.78B |
| Halozyme Therapeutics, Inc. | 16.24B |
| Neurocrine Biosciences, Inc. | 14.51B |
| Agenus, Inc. | 534.42M |
| Anika Therapeutics, Inc. | 273.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 78.40M |
| Revenue (Quarterly) | 218.25M |
| Total Expenses (Quarterly) | 139.86M |
| EPS Diluted (Quarterly) | 0.2957 |
| Gross Profit Margin (Quarterly) | 98.01% |
| Profit Margin (Quarterly) | 35.92% |
| Earnings Yield | -19.66% |
| Operating Earnings Yield | 21.25% |
| Normalized Earnings Yield | 7.299 |